Skip to main content
Clinical Trials/NCT05372523
NCT05372523
Terminated
Not Applicable

Pilot Investigation of Senseye's Ocular Brain-Computer Interface (OBCI) for Diagnosis of Adult With Post-Traumatic Stress Disorder (PTSD)

Senseye, Inc.1 site in 1 country61 target enrollmentApril 25, 2022
ConditionsPTSD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
PTSD
Sponsor
Senseye, Inc.
Enrollment
61
Locations
1
Primary Endpoint
Feasibility of the Senseye tool
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

This pilot study will investigate the feasibility, acceptability, repeatability, accuracy and efficacy of the Senseye OBCI diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. A total of 68 adults will be included in the study with a follow-up time point of 9 weeks post-initial intervention.

Detailed Description

This pilot study will investigate the feasibility, acceptability, repeatability, accuracy, and efficacy of operator-independent Senseye Ocular Brain-Computer Interface (OBCI) diagnostic tool to assess the presence and severity of PTSD symptoms and monitor response to trauma-informed interventions. After informed consent, 68 adults - 34 with PTSD and 17 adults with significant trauma exposure but no PTSD, and 17 healthy adults without known major psychiatric disorders, aged 18-65 years old, will be recruited and undergo OBCI diagnostic tool, comparing against gold standards tools- the CAPS-5, UCLA PTSD Reaction Index for DSM-5 (PTSD-RI). Fifteen participants will undergo repeatability and reproducibility assessments. Adults with PTSD will receive a standard of care trauma-informed interventions for eight weeks, and their biopsychosocial characteristics, Senseye OBCI, neuropsychiatric measures will be measured at baseline and week 9. Using Senseye's machine learning algorithm, Senseye OBCI will use a facecam recorder during a series of visual tasks, pupil light reflex, and heart rate measurement throughout.

Registry
clinicaltrials.gov
Start Date
April 25, 2022
End Date
January 11, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male/Female diagnosed with PTSD (only for PTSD group)
  • aged 18- 65 years old
  • able to read/write in English

Exclusion Criteria

  • presence of intellectual disabilities
  • psychotic or self-injurious behavior
  • seizure disorder
  • major depression
  • traumatic brain injury (TBI)
  • language disorder
  • eye disorders
  • other neurodevelopmental disorders
  • history of lifetime psychosis
  • current suicidality

Outcomes

Primary Outcomes

Feasibility of the Senseye tool

Time Frame: 9 weeks

Feasibility will be assessed by evaluating retention rate.

Agreement between Senseye OBCI measures and gold-standard measures

Time Frame: 9 weeks

Assessments for the presence and severity of PTSD symptoms will be compared between the Senseye tool and the gold-standard measures for percent agreement.

Test-retest for repeatability of the Senseye tool

Time Frame: 1 week

Senseye OBCI assessments will be repeated the same day and again at one week.

Secondary Outcomes

  • Prognostic value by comparing Senseye OBCI to core PTSD symptoms(9 weeks)

Study Sites (1)

Loading locations...

Similar Trials